Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Recruiting
Shandong University
Phase 2
2021-03-31
The study is a multi-center, prospective, one-arm, phase II clinical trial. It is tend to
examine the safety and efficacy of combining abraxane(albumin-bound paclitaxel） and
bevacizumab to treat patients with recurrent, platinum-resistant primary epithelial ovarian
cancer, fallopian tube cancer or peritoneal carcinoma.
Intravenous Immunoglobulin Therapy in Optic Neuritis
Completed
National Eye Institute (NEI)
Phase 3
1995-08-01
To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than
placebo in restoring lost visual function (visual acuity) in optic neuritis (ON).
To determine the time course of recovery following IVIg administration. If the reports of
IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can
be confirmed, this would provide indirect evidence that IVIg may promote central nervous
system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).
Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1975-11-01
To evaluate whether hepatitis B immune globulin with a high level of antibody against the
hepatitis B antigen would be capable of interrupting maternal-fetal transmission of hepatitis
B virus, the single most important route of hepatitis spread in the entire Third World.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
